
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher Corporation has demonstrated significant growth prospects, with performance obligations increasing to $4.9 billion in Q2 2025, up from $4.5 billion in Q1 2025, indicating strong demand for its products. The company is projected to experience a 4.5% growth ramp in its Life Sciences segment during Q4 2025, driven by favorable comparisons in Genomics and contributions from new product launches, alongside an improving performance in China. Additionally, the Cepheid Respiratory business is expected to generate substantial revenue, with forecasts suggesting $300-350 million in Q3 2025 and $450-500 million in Q4 2025, reflecting a strong positioning in the diagnostic market.
Bears say
Danaher's financial outlook exhibits a concerning trend as the percentage of obligations expected to be recognized as revenue within the next 12 months has decreased from 48% to 46%, indicating a potential slowdown in revenue generation. Additionally, the company faces substantial risks associated with geopolitical disruptions, foreign exchange fluctuations, and the uncertainty of recovery in high-growth end-markets, notably in China. Despite some confidence regarding biotechnology and life sciences revenue, the overall guidance has come in slightly below expectations for 3Q25, suggesting that growth may not proceed as favorably as anticipated.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares